Moreover, although TB treatment with rapamycin and everolimus would rely on fundamentally similar mechanisms, the key differences in mTOR pathway modulation between these two drugs implies a possible improvement in outcomes with everolimus use [15]. Here, MTOR is linked to tuberculosis.